LOWY 2015* TESTING HIGH RISK CHILDHOOD CANCER PATIENT CELLS IN VITRO FOR POTENTIAL NEW DRUG TREATMENTS (#101)
2:15 PM
Global Demethylation Increases XPC Expression and Overcomes Platinum Therapy Resistance in Melanoma (#102)
2:15 PM
Identification of a novel glucose oxidation agonist that selectively kills cancer cells (#103)
2:15 PM
Investigating acquired resistance to novel Pol I transcription inhibitors for the treatment of haematologic malignancies (#104)
2:15 PM
Novel approaches to targeting the tumour-stroma coalition in triple negative breast cancers (#105)
2:15 PM
High-throughput screening identifies new inhibitors of the multidrug transporter MRP4 (#106)
2:15 PM
Establishing in vitro and in vivo models to develop novel therapeutic approaches for Diffuse Intrinsic Pontine Glioma. (#108)
2:15 PM
TP53 mutation and p53 immunohistochemistry in high grade serous ovarian cancer. (#109)
2:15 PM
The Bright Alliance - new ways of working (#110)
2:15 PM
Mitochondrial and mTOR pathway inhibition synergise to block pancreatic adenocarcinoma development (#111)
2:15 PM
EPIGENETICS INFORMING FUTURE TREATMENT STRATEGIES FOR HIGH GRADE SEROUS OVARIAN CANCER – LOOKING TO HISTONES, UBIQUITIN AND CHROMATIN RELAXATION (#112)
2:15 PM
A comprehensive and systematic analysis of miRNA function in neuroblastoma (#113)
2:15 PM
Stathmin mediates neuroblastoma metastasis in a tubulin-independent manner via RhoA activation and transendothelial migration (#114)
2:15 PM
A novel anti-cancer agent that sensitizes neuroblastoma cells to chemotherapy and targets cellular metabolism (#115)
2:15 PM
MYCN coordinately regulates the entire polyamine pathway to maintain high polyamine levels in neuroblastoma (#116)
2:15 PM
Investigating the therapeutic potential of targeting ABCE1 in neuroblastoma (#117)
2:15 PM
Targeting transcription factors in cancer – a hard road, but more likely to reach the destination? (#118)
2:15 PM
BET-bromodomain inhibition induces Myc-independent apoptosis via epigenetic regulation of BCL-2 family proteins in aggressive Myc-driven lymphoma. (#119)
2:15 PM
Transcriptional regulation of mammary gland lineage commitment by Inhibitor of Differentiation 4 (Id4) (#120)
2:15 PM
The glucocorticoid receptor coordinately regulates BIM and BCL2 in paediatric acute lymphoblastic leukaemia cells (#122)
2:15 PM
BIOLUMINESCENCE IMAGING ENHANCES ANALYSIS OF DRUG RESPONSE IN A PATIENT-DERIVED XENOGRAFT MODEL OF PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA (#123)
2:15 PM
An 18-gene Myc activity signature for neuroblastoma and other Myc-driven cancers (#124)
2:15 PM
Modelling personalised medicine in high-risk neuroblastoma (#125)
2:15 PM
Discovery of a small molecule TUBB3/βIII-tubulin modulator in lung cancer (#126)
2:15 PM
Assessing an in vitro model of cultured patient-derived xenografts for predicting treatment response in vivo (#127)
2:15 PM
Involvement of ATM in the recruitment of human telomerase to telomeres (#128)
2:15 PM
Disabled negative feedback regulation by SPROUTY2 sustains EGFR, FGFR and c-MET mediated resistance to BRAF inhibitor treatment in melanoma (#130)
2:15 PM
The novel long non-coding RNA RP1X induces N-Myc protein stabilization, tumour cell proliferation and survival (#131)
2:15 PM
THE ACRF DRUG DISCOVERY CENTRE: AN EARLY-STAGE DRUG DISCOVERY SERVICE (#132)
2:15 PM
NOVEL THERAPEUTICS FOR MIXED LINEAGE LEUKAEMIA IN INFANTS (#133)
2:15 PM
The renin angiotensin system in endometrial cancer (#134)
2:15 PM
MEK inhibition and models of resistance in acute myeloid leukaemia. (#135)
2:15 PM
CBL0137, a novel NFkB suppressor and p53 activator, is highly effective in two independent pre-clinical mouse models of neuroblastoma (#136)
2:15 PM
Development and characterisation of Aurora A kinase inhibitor MLN8237 resistant leukaemia cells (#137)
2:15 PM
Protein-protein docking for the discovery of novel therapeutics that target the interaction between PTP1B and EGFR (#138)
2:15 PM
ßIII-Tubulin supports cell growth and proliferation of glucose-starved Non-small Cell Lung Cancer cells by modulating multiple stress response signalling pathways. (#139)
2:15 PM
Stathmin regulation of microRNA/mRNA expression in neuroblastoma cells (#140)
2:15 PM
Do patients with advanced cancer want to discuss and pay for unfunded expensive anticancer drugs? (#141)
2:15 PM
Mechanistic insights into HDAC-inhibitors: Linking the Type-I Interferon Signaling Pathway with Differentiation Therapy in t(8;21) AML (#142)
2:15 PM
Systematic Identification of Ubiquitin Ligase Substrates (#143)
2:15 PM
Identifying novel cancer cell susceptibilities (#144)
2:15 PM
Harnessing the power of serum microRNAs to predict surgical outcome for women with ovarian cancer (#145)
2:15 PM
UBR5 Regulates Primary Cilia Formation via Interactions with Multiple Centriollar Proteins (#146)
2:15 PM
A role for the free beta subunit of human chorionic gonadotropin in sensitivity of high grade serous cancer cells to platinum-based chemotherapeutics (#147)
2:15 PM
Functional genomics of BRAF-driven glycolysis in BRAFV600 melanoma (#148)
2:15 PM
A novel molecule targeting protein translation, rapidly and selectively induces cell death in Mixed Lineage Leukaemia (#149)
2:15 PM
New Approach to AML Therapy: Inhibition of rDNA Transcription by CX-5461 (#150)
2:15 PM
Discovery of CTx-0391034 a novel potent and selective inhibitor of PRMT5 (#151)
2:15 PM
Identification of a novel compound that synergistically inhibits cell growth with BRAF inhibitor in BRAF wildtype and NRAS mutant melanoma cells (#152)
2:15 PM
THIOIMIDAZOLINE BASED COMPOUNDS REVERSE GLUCOCORTICOID RESISTANCE IN PAEDIATRIC ACUTE LYMPHOBLASTIC LEUKAEMIA (#153)
2:15 PM
Therapeutic targeting of the MYC signal by inhibition of histone chaperone FACT in neuroblastoma (#154)
2:15 PM
Targeting mitochondrial function and the PI3K/AKT/mTOR pathway as a novel therapeutic approach in the treatment of Diffuse Intrinsic Pontine Glioma (#155)
2:15 PM
PP2A - a novel biomarker and therapeutic target for poor outcome breast cancer (#156)
2:15 PM
Targeting copper metabolism in neuroblastoma using Dextran-Catechin (#157)
2:15 PM
Molecular profiling to predict drug sensitivity or resistance in relapsed childhood cancer (#158)
2:15 PM
The prorenin receptor as a novel therapeutic target for the treatment of endometrial cancer (#159)
2:15 PM
Cell cycle checkpoint inhibition and cyclophosphamide is an effective combination therapy in a mouse model of paediatric medulloblastoma (#160)
2:15 PM
Increased density of somatic mutations at core promoters is linked to neutral selection and transcriptional activity (#161)
2:15 PM
M606, a novel small molecule inhibitor of MYCN oncoprotein (#162)
2:15 PM
Effect of combining EGFR-targeted therapy and metabolic inhibitors in the treatment of sarcoma (#163)
2:15 PM
New, highly selective MRP1 inhibitors show promising preclinical activity in neuroblastoma (#164)
2:15 PM